Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae.

Antimicrobial Agents and Chemotherapy
Deverick J AndersonKeith S Kaye

Abstract

Bloodstream infection (BSI) due to multidrug-resistant Klebsiella is associated with high rates of morbidity and mortality. The aim of this study was to identify predictors of in-hospital mortality among patients with BSI due to ceftazidime-resistant (CAZ-R) Klebsiella pneumoniae at a tertiary care medical center. Patients with CAZ-R K. pneumoniae BSI were identified by our microbiology laboratory between January 1995 and June 2003. Clinical data were collected retrospectively. Logistic regression was used to identify independent predictors of all causes of in-hospital mortality. Of 779 patients with K. pneumoniae BSI, 60 (7.7%) had BSI due to CAZ-R K. pneumoniae; 43 (72%) of these were nosocomial infections. Pulsed-field gel electrophoresis identified a single predominant strain in 17 (28%) patients. The in-hospital mortality rate was 43% (n = 26). Among patients with CAZ-R K. pneumoniae BSI, those who died were similar to survivors with respect to demographic, clinical, and antimicrobial susceptibility characteristics. Only 43 (72%) patients received effective therapy within 5 days of BSI. In bivariable analysis, delay in initiation of effective therapy for >72 h after diagnosis of BSI was associated with death (P = 0.03). St...Continue Reading

References

Jun 1, 1988·American Journal of Infection Control·J S GarnerJ M Hughes
Sep 1, 1993·Annals of Internal Medicine·K S MeyerJ J Rahal
Jul 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L B RiceD M Shlaes
Mar 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J C LucetB Regnier
Jun 1, 1997·Infectious Disease Clinics of North America·S K FridkinR A Weinstein
Dec 10, 1998·Journal of Internal Medicine·L LeiboviciS D Pitlik
May 29, 1999·Antimicrobial Agents and Chemotherapy·F DanelD M Livermore
Jun 1, 2000·Infectious Disease Clinics of North America·K S KayeE Abrutyn
Feb 13, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D L Paterson
Mar 27, 2001·MMWR. Morbidity and Mortality Weekly Report·UNKNOWN Centers for Disease Control and Prevention (CDC)
Apr 3, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E LautenbachN O Fishman
Apr 26, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P L WinokurN Legakis
Dec 12, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Annie Wong-BeringerKaren Bush
Dec 26, 2001·Antimicrobial Agents and Chemotherapy·Alain PhilipponGeorge A Jacoby
Jan 17, 2002·Pharmacotherapy·Allison E EinhornSusan L Pendland
Jul 29, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sujata M BhavnaniPaul G Ambrose
Sep 5, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cheol-In KangKang-Won Choe
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·R Bonnet
Dec 31, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rodger D MacArthurWilliam Barchuk
Jun 19, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David L PatersonVictor L Yu
Aug 17, 2004·Infectious Disease Clinics of North America·Keith S KayeElias Abrutyn
Dec 2, 2004·American Journal of Infection Control·UNKNOWN National Nosocomial Infections Surveillance System
Jan 28, 2005·The New England Journal of Medicine·George A Jacoby, Luisa Silvia Munoz-Price

❮ Previous
Next ❯

Citations

Sep 16, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marin H KollefScott T Micek
Dec 12, 2007·Antimicrobial Agents and Chemotherapy·Christian G GiskeUNKNOWN ReAct-Action on Antibiotic Resistance
Apr 29, 2011·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Elif Sahin HorasanAli Kaya
Dec 12, 2012·Journal of Clinical Medicine Research·Jose OrsiniGeorge Sakoulas
Dec 15, 2010·Critical Care Clinics·Duane J Funk, Anand Kumar
Apr 7, 2009·Diagnostic Microbiology and Infectious Disease·Mario TumbarelloLivio Pagano
Jun 10, 2015·Jornal de pediatria·Patrícia de Oliveira CostaAndré Ricardo Araújo da Silva
Apr 10, 2008·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Birgitta LytsyAsa Melhus
Jul 25, 2006·Expert Opinion on Pharmacotherapy·Julio A Ramirez
Nov 15, 2014·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Seung Beom HanYeon-Joon Park
Jan 15, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pranita D TammaUNKNOWN Antibacterial Resistance Leadership Group
Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
Oct 1, 2013·Expert Review of Anti-infective Therapy·Pierluigi VialeMario Tumbarello
Jun 22, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Olfa DziriChedly Chouchani
Oct 14, 2008·Expert Review of Anti-infective Therapy·Jesús Rodríguez-Baño, Alvaro Pascual
Jul 14, 2007·The Journal of Antimicrobial Chemotherapy·Sarjana JainNigel Brenwald
Feb 26, 2021·Pharmacological Reviews·Sue C NangJian Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Thomas P LodiseMichael J Rybak
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
R ZaragozaJ M Nogueira
© 2022 Meta ULC. All rights reserved